Skip to content

Clinical study of cervical sympathetic nerve regulation in the treatment of diabetic peripheral neuropathy

Clinical study of cervical sympathetic nerve regulation in the treatment of diabetic peripheral neuropathy

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035544
Enrollment
Unknown
Registered
2020-08-13
Start date
2020-08-13
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic peripheral neuropathy

Interventions

Intervention group vs drug group:cervical sympathetic nerve regulation therapy

Sponsors

Shanghai 10th People's Hospital,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 75 years; 2. All meet the diagnostic criteria for diabetes (2014 American Guidelines for Diabetes: Diagnostic criteria for Diabetes); 3. With clinical symptoms and signs of diabetic peripheral neuropathy: numbness, pain, ant walking, burning and cooling in the limbs, which are distributed like gloves and stockings. The patients' sense of touch, pain and warmth are weakened, and the knee-tendon and Achilles tendon reflex are weakened or completely disappeared;Or emG shows multiple peripheral neuropathy; 4. BMI 16-27; 5. Patients voluntarily sign informed consent and can be followed up as scheduled.

Exclusion criteria

Exclusion criteria: 1. Other diseases that cause peripheral neuropathy (cerebral infarction, hyperthyroidism, hypothyroidism, vitamin B12 deficiency, folic acid deficiency, Guillembarr syndrome, cervical disc herniation, lumbar intervertebral disc herniation, vascular disease, radiotherapy, post-chemotherapy, long-term hormone use, sysy-positive, heavy alcohol consumption, etc.); 2. Severe, progressive, uncontrolled diseases of vital organs and systems (including cardiovascular, liver, lung, and kidney), bleeding tendency due to coagulation factor deficiency, autoimmune diseases, malignant tumors, and other diseases that the researchers deem inappropriate to participate in this study; 3. Received sympathetic nerve regulation therapy in recent 3 months; 4. Women who are pregnant, lactating or planning to become pregnant within one year; 5. Received analgesic and anti-inflammatory drugs and anticonvulsant drugs in the last 3 months.

Design outcomes

Primary

MeasureTime frame
VAS;

Countries

China

Contacts

Public ContactFuqing Lin

Shanghai 10th People's Hospital

15800552155@163.com+86 18917684132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026